InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,048.42
(
-0.46%
)
US TECH 100
17,224.40
(
0.96%
)
Dow Jones
38,085.80
(
-0.98%
)
Brent Oil
88.06
(
0.96%
)
Bitcoin
64,879.65
(
0.93%
)
Post# of 251599
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 827
Posts 119482
Boards Moderated 15
Alias Born 09/05/2002

DewDiligence

Member Level

Re: JohnWayne post# 208210

Friday, 09/22/2017 10:38:04 AM

Friday, September 22, 2017 10:38:04 AM

Post# of 251599
Japan approves Opdivo monotherapy for second-line gastric cancer—a very common disease in Asia:

https://finance.yahoo.com/news/japan-ministry-health-labor-welfare-090000008.html

The basis for approval was Ono’s phase-3 trial that had HR=0.63 for Opdivo OS vs placebo (#msg-127976936). Patients in the trial were from Japan, Korea, and Taiwan.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up